Evaluating congestion in chronic heart failure patients
Évaluation de la Congestion en Ambulatoire Chez Les Patients Atteints d'Insuffisance Cardiaque Chronique. CHF-COV (Chronic Heart Failure - COngestion eValuation)
NA · Central Hospital, Nancy, France · NCT05089149
This study is trying to find out if certain signs of congestion in people with chronic heart failure can help predict their risk of being hospitalized or dying within two years.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France (other) |
| Locations | 2 sites (Vandœuvre-lès-Nancy and 1 other locations) |
| Trial ID | NCT05089149 on ClinicalTrials.gov |
What this trial studies
This study focuses on chronic heart failure (HF) patients, particularly those experiencing congestion, which is a major cause of hospitalization and symptoms. It aims to identify various congestion markers through clinical examinations, laboratory tests, and ultrasound evaluations during a scheduled consultation or day hospitalization. The study will monitor these markers to assess their association with the risk of all-cause death or hospitalization for acute HF within 24 months. By integrating multiple evaluation methods, the study seeks to enhance the understanding of congestion in HF management.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with chronic heart failure admitted for scheduled hospitalization or consultation.
Not a fit: Patients with severe comorbidities, those on dialysis, or individuals unable to provide consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management strategies for chronic heart failure patients, potentially reducing hospitalizations and mortality.
How similar studies have performed: Other studies have shown success in using multi-modality evaluations for heart failure management, suggesting this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with chronic acute heart failure admitted in hospital for scheduled day hospitalization or consultation * Age ≥18 years * Patients having received complete information regarding the study design and having signed their informed consent form. * Patient affiliated to or beneficiary of a social security scheme. Exclusion Criteria: * Comorbidity for which the life expectancy is ≤ 3 months * Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate \<15 ml/min/m2 at inclusion. * History of lobectomy or pneumonectomy lung surgery * Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc. * Pregnant woman, parturient or nursing mother * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * Adult person who is unable to give consent * Person deprived of liberty by a judicial or administrative decision, * Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.
Where this trial is running
Vandœuvre-lès-Nancy and 1 other locations
- CHRU de Nancy — Vandœuvre-lès-Nancy, France (RECRUITING)
- CHRU de Nancy — Vandœuvre-lès-Nancy, France (NOT_YET_RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Heart Failure